Corresponding Author	Clément Gourguechon
List all other authors	Julien Rossignol1, Cristina Bulai Livideanu2, Maël Heiblig3, Stéphane Barete4, Yannick Chantran5, Philippe Guilpain6, Aurélie Schieffmann6, Olivier Tournilhac7, David Launay8,9, Louis Terriou8,9, Laurence Bouillet10, Ghandi Damaj11, Yannick Degboé12, Thomas Ballul13, Céline Greco14, Laurent Frenzel13, Cécile Meni13, Caroline Gaudy-Marqueste15, Marie Gousseff16, Edwige Le Mouel17, Sophie Besnard17, Antoine Neel18, Dana Ranta19, Roland Jaussaud20, Julie Bruneau21, Rose-Marie Javier22, Florence Castelain23, Quentin Cabrera24, Marie Pierre Gourin25, Ewa Wierzbicka-Hainaut26, Christian Lavigne27, Cyrille Hoarau28, Sophie Dimicoli-Salazar29, Audrey Duval30, Nicolas Garcelon30, Angèle Soria31, Michel Arock32, Olivier Lortholary13, Hassiba Bouktit13, Ludovic Lhermitte33,34, Omer Beganovic33,34, Orianne Debeaupuis13,† , Olivier Hermine13,*†, Julien Rossignol13,*,†
Email-Address	julien.rossignol@aphp.fr
Institute/Department	CEREMAST, Imagine Institute, INSERM U1163, AP-HP, Necker-Enfants Malades Hospital, Paris Cité University
Address of Institute	149 rue de Sevres, Paris, France
Title of Presentation	Avapritinib improves quality of life in indolent systemic mastocytosis: a prospective nationwide real-world study
abstract-hint	
Abstract of Presentation	Avapritinib, a selective KIT D816V inhibitor, has demonstrated efficacy in indolent systemic mastocytosis (ISM) in the PIONEER trial, but real-world data remain limited. The AIMS study is a prospective, multicenter, observational study across 21 French CEREMAST centers (NCT06186856). Adults with ISM or bone marrow mastocytosis (BMM) initiating avapritinib 25 mg daily were enrolled between April 2024 and April 2026. Of 229 patients, 216 with ISM/BMM were eligible; 173 constituted the tolerance

	cohort and 98 the efficacy cohort (paired baseline–month 6 data). Median age was 51 years, 59% female, 91% had cutaneous involvement, and 86% carried KIT D816V. At 6 months, MC-QoL improved from 48.5 to 29.0 (P<0.001), ISM-SAF score from 29.0 to 16.0 (P<0.001), serum tryptase from 42.3 to 17.8 μg/L (P<0.001), and KIT D816V variant allele frequency from 0.8% to 0.4% (P<0.001). Among 57 patients with maculopapular cutaneous mastocytosis, 46% achieved complete or good partial response. Improvements spanned all MC-QoL domains. A symptom-to-function mapping analysis revealed that fatigue and flush improvements most strongly predicted functional gains. None of the patients experienced a serious adverse event. Only 8 patients (4.6%) discontinued due to adverse events. This largest real-world avapritinib study in ISM demonstrates significant 6-month benefits with favorable tolerability in routine practice. Presenting author: Clément Gourguechon